Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly  Settings
FUSN Fusion Pharmaceuticals Inc. daily Stock Chart
FUSN [NASD]
Fusion Pharmaceuticals Inc.
Healthcare | Biotechnology | Canada
statements
Index- P/E- EPS (ttm)-17.69 Insider Own9.00% Shs Outstand41.66M Perf Week-2.04%
Market Cap502.92M Forward P/E- EPS next Y-0.17 Insider Trans0.00% Shs Float18.87M Perf Month-6.60%
Income-65.10M PEG- EPS next Q-0.14 Inst Own81.80% Short Float1.06% Perf Quarter-21.95%
Sales- P/S- EPS this Y-38.90% Inst Trans- Short Ratio1.61 Perf Half Y-
Book/sh133.21 P/B0.09 EPS next Y-41.70% ROA- Target Price- Perf Year-
Cash/sh7.62 P/C1.58 EPS next 5Y- ROE- 52W Range11.71 - 19.00 Perf YTD-29.29%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-36.74% Beta-
Dividend %- Quick Ratio42.10 Sales past 5Y- Gross Margin- 52W Low2.65% ATR0.53
Employees41 Current Ratio42.10 Sales Q/Q- Oper. Margin- RSI (14)39.44 Volatility6.40% 3.90%
OptionableNo Debt/Eq0.00 EPS Q/Q- Profit Margin- Rel Volume0.17 Prev Close11.80
ShortableYes LT Debt/Eq0.00 EarningsAug 11 BMO Payout- Avg Volume124.73K Price12.02
Recom1.50 SMA20-3.52% SMA50-7.56% SMA200-13.29% Volume22,551 Change1.86%
Jul-21-20Initiated Wedbush Outperform $25
Jul-21-20Initiated Jefferies Buy $25
Jul-21-20Initiated Cowen Outperform
Sep-29-20 04:15PM  
Fusion Pharmaceuticals Appoints Maria Stahl as Chief Legal Officer
CNW Group
Sep-27-20 10:18AM  
Should You Take Comfort From Insider Transactions At Fusion Pharmaceuticals Inc. (NASDAQ:FUSN)?
Simply Wall St.
Sep-10-20 09:00AM  
Fusion Pharmaceuticals to Present at the Morgan Stanley Virtual 18th Annual Global Healthcare Conference
PR Newswire
09:00AM  
Fusion Pharmaceuticals to Present at the Morgan Stanley Virtual 18th Annual Global Healthcare Conference
CNW Group
Aug-11-20 07:25AM  
Fusion Pharmaceuticals Announces Second Quarter 2020 Financial Results and Business Update
PR Newswire
Aug-05-20 08:00AM  
Fusion Pharmaceuticals to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference
PR Newswire
Jul-14-20 09:30AM  
H1 2020 Canadian IPO - CSE leads in number of non-CPC/SPAC IPOs (88%), GFL IPO accounts 77% of IPO amount
CNW Group
Jul-10-20 05:13PM  
e.l.f. Beauty, Akouos See Activist Actions
Barrons.com
Jun-25-20 10:39PM  
Fusion Pharmaceuticals Announces Pricing of Initial Public Offering
PR Newswire
10:39PM  
Fusion Pharmaceuticals Announces Pricing of Initial Public Offering
CNW Group
Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines. The company has developed Targeted Alpha Therapies platform together with its proprietary Fast-Clear linker technology to enable us to connect alpha particle emitting isotopes to antibodies and other targeting molecules in order to selectively deliver the alpha particle payloads to tumors. Its lead product candidate is FPI-1434 that is in Phase 1 clinical trials as a monotherapy in patients with solid tumors expressing insulin-like growth factor 1 receptor. The company is also conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, it is progressing its earlier-stage product candidate, FPI-1966 into clinical development for the treatment of head and neck, and bladder cancers expressing fibroblast growth factor receptor. The company was founded in 2014 and is headquartered in Hamilton, Canada.
open in yahoo | open in reuters | open in google